default author photo

Hui Wang

Southern University of Science and Technology - Shenzhen Third People's Hospital

Shenzhen

China

SCHOLARLY PAPERS

1

DOWNLOADS

154

TOTAL CITATIONS

2

Scholarly Papers (1)

1.

Efficacy and Safety of Long Acting HIV Fusion Inhibitor Albuvirtide in Antiretroviral-Experienced Adults with HIV-1: Interim 48 Week Results from the Randomized, Controlled, Phase 3 Trial, Non-Inferiority TALENT Study

Number of pages: 27 Posted: 08 Jan 2019
Capital Medical University - Beijing YouAn Hospital, Frontier Biotechnologies Inc., Capital Medical University, Fudan University - Department of Radiology, Government of the People's Republic of China - Tangdu Hospital, The First Hospital of Changsha, Southern University of Science and Technology - Shenzhen Third People's Hospital, Central South University - Second Xiangya Hospital, Zhejiang University - First Affiliated Hospital, Zhejiang Chinese Medical University - Xixi Hospital of Hangzhou, Government of the People's Republic of China - 302 Military Hospital, Capital Medical University - Beijing Ditan Hospital, Capital Medical University - Beijing YouAn Hospital, Capital Medical University - Center for Infectious Diseases, Shanghai University of Traditional Chinese Medicine, Beijing Co-CRO Medical Development Co., Ltd., Frontier Biotechnologies Inc., Frontier Biotechnologies Inc., Chinese Center for Disease Control and Prevention (China CDC) - National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC) - National Center for AIDS/STD Control and Prevention, Zhengzhou University, Guangzhou Medical University - Guangzhou Eighth People's Hospital, Capital Medical University - Clinical and Research Center for Infectious Diseases, Frontier Biotechnologies Inc. and Independent
Downloads 154 (482,968)
Citation 2

Abstract:

Loading...

HIV; fusion inhibitor; albuvirtide; LPV/r; non-inferiority; phase 3 clinical trial